Why ResMed Inc. (RMD) stock moved
ResMed Inc. (RMD) shares fell 0.2% to $198.61 as of July 21, 2026, a slight decline from the prior close of $198.99. BestStocks flagged the session as a material change for RMD. Below, we break down what changed for RMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RMD fell 0.2% to $198.61
RMD fell 0.2% in its latest session, moving from $198.99 to $198.61.
What it means for ResMed Inc. investors
For ResMed Inc. investors, the recent signals add up to a bearish shift. On the constructive side: ResMed Inc. (RMD) moved +2.88% from $193.01 to $198.57 on 2026-07-15; ResMed Inc. (RMD) moved +4.18% from $209.63 to $218.40 on 2026-07-06, reaching a new 30-day high on significantly elevated volume (2.6x the 5-day average). Weighing against that: Negative session, down 0.2%; ResMed Inc. (RMD) moved −2.77% from $198.50 to $193.01 on 2026-07-14. Wall Street's consensus price target sits at $242.00, implying +21.8% upside from $198.61. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 16 days out, the next report is the most likely near-term test of the move.
RMD price reaction
RMD last traded at $198.61, down $0.38 (-0.19%) from the previous close of $198.99. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $188.45 and $219.75, and it currently sits about 32% of the way up that band.
Bullish and bearish analyst opinions on ResMed Inc. (RMD)
The consensus analyst price target on ResMed Inc. (RMD) is $242.00, 21.8% above the recent $198.61. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 2 downgrades. Here is how the bullish and bearish cases on RMD line up.
The bullish case
- Wall Street's consensus price target of $242.00 implies +21.8% upside from $198.61.
- The Street's most bullish target is $275.00 (+38.5%).
- ResMed Inc. (RMD) moved +2.88% from $193.01 to $198.57 on 2026-07-15.
The bearish case
- 2 analyst downgrades in the past 90 days, most recently Citigroup to Neutral (2026-07-13).
- Negative session, down 0.2%.
- ResMed Inc. (RMD) moved −2.77% from $198.50 to $193.01 on 2026-07-14.
- RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RMD
Frequently asked questions about RMD
Why did ResMed Inc. (RMD) stock move?
RMD fell 0.2% to $198.61. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RMD stock fall?
RMD lost 0.19% ($0.38) versus the prior close of $198.99, last trading at $198.61 on 0.5× average volume.
When is ResMed Inc.'s next earnings date?
RMD's next earnings report is estimated for 2026-08-06 — about 16 days away.
What is the analyst price target for RMD?
The consensus analyst price target for RMD is $242.00, about 21.8% above the current $198.61. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 2 downgrades.
How BestStocks tracks RMD
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RMD-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for RMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.